Skip to main content
SpringerLink
Log in

Prevention of and Medical Therapy for Atrial Arrhythmias in Heart Failure

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

A large proportion of heart failure patients suffer from atrial arrhythmias, prime amongst them being atrial fibrillation (AF). Ventricular dysfunction and the syndrome of heart failure can also be a concomitant pathology in up to 50% of patients with AF. However this association is more than just due to shared risk factors, research from animal and human studies suggest a causal relationship between AF and heart failure. There are numerous reports of tachycardia-induced heart failure where uncontrolled ventricular rate in AF results in heart failure, which is reversible with cardioversion to sinus rhythm or ventricular rate control. However the relationship extends beyond tachycardia-induced cardiomyopathy. Optimal treatment of AF may delay progressive ventricular dysfunction and the onset of heart failure whilst improved management of heart failure can prevent AF or improve ventricular rate control. Prevention and treatment of atrial arrhythmias, and in particular atrial fibrillation, is therefore an important aspect of the management of patients with heart failure.

This review describes the incidence and possible predictors of AF and other atrial arrhythmias in patients with heart failure and discusses the feasibility of primary prevention. The evidence for the management of atrial fibrillation in heart failure is systematically reviewed and the strategies of rate versus rhythm control discussed in light of the prevailing evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch Intern Med1988;148(9): 201–2016.

    Google Scholar 

  2. Opasich C, Febo O, Riccardi PG, Traversi E, Forni G, et al. Concomitant factors of decompensation in chronic heart failure. Am J Cardiol1996;78(3): 35–357.

    Google Scholar 

  3. Pozzoli M, Cioffi G, Traversi E, Pinna G, Cobelli F, et al. Predictors of primary atrial fibrillation and concomitant clinical and haemodynamic changes in patients with chronic heart failure: A prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol1998;32(1):19–204.

    Google Scholar 

  4. Crijns HJGM, Van Den Berg MP, Van Gelder IC, Veldhuisen DJV. Management of atrial fibrillation in the setting of heart failure. Eur Heart J1997;18(suppl.C):C4–49.

    Google Scholar 

  5. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol1992;69:157–1573.

    Google Scholar 

  6. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronically rapidly conducted atrial fibrillation: Complete recovery after restoration of sinus rhythm. Am J Med1988;85:24–244.

    Google Scholar 

  7. Haiat R, Halphen C, Stoltz JP, Leroy G, Sousanna C. Atrial fibrillation: A cause of reversible cardiomyopathy. Ann Cardiol Angeiol1987;36(8):41–419.

    Google Scholar 

  8. Brill IC. Congestive cardiac failure arising from uncontrolled auricular fibrillation in the otherwise normal heart: Follow-up notes on a previousy reported case. Am J Med1947;2:544.

    Google Scholar 

  9. Mostow ND, Vrobel TR, Noon D, Rakita L. Rapid control of refractory atrial tacharrythmia with high-dose oral amiodarone. Am Heart J1990;120:1356.

    Google Scholar 

  10. Van Den Berg MP, Tuinenberg AE, Crijns HJGM, Van Gelder IC, Gosselink ATM, Lie KI. Heart failure and atrial fibrillation: Current concepts and controversies. Heart1997;77(4):30–313.

    Google Scholar 

  11. Cioffi G, Pozzoli M, Forni G, et al. Systemic thromboembolism in chronic heart failure: A prospective study in 406 patients. Eur Heart J1996;17:138–1389.

    Google Scholar 

  12. Khand AU, Gemmel I, Rankin AC, Cleland JGF. Clinical events leading to the progression of heart failure: Insights from a national database of hospital discharges. Eur Heart J2001;22(2):15–164.

    Google Scholar 

  13. Mathew J, Hunsberger S, Fleg J, Mcsherry F, Wiliford W, Yusuf S, for the Digitalis Investigators. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest2000;118:91–922.

    Google Scholar 

  14. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol1998;32:20–210.

    Google Scholar 

  15. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol1994;74:23–241.

    Google Scholar 

  16. Blackshear JL, Kopecky SL, Safford RE, et al. Management of atrial fibrillation in adults: Prevention of thromboembolism and symptomatic treatment. Mayo Clin Proc1996;71:15–160.

    Google Scholar 

  17. Kannel WB, Abbott RD, Savage DD, Mcnamara PM. Epidemiological features of chronic atrial fibrillation. N Eng J Med1982;306:101–1022.

    Google Scholar 

  18. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J1991;121:95–957.

    Google Scholar 

  19. Tavazzi L. Epidemiological burden of heart failure. Heart1998;79:S–S9.

    Google Scholar 

  20. Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, et al. Readmission after hospitalization for congestive heart failure among medicare beneficiaries. Arch Intern Med1997;157:9–104.

    Google Scholar 

  21. Vinson JM, Rich MW, Sperry JC, et al. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc1990;38:129–1295.

    Google Scholar 

  22. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart1998;80:43–441.

    Google Scholar 

  23. Yamada T, Fukunami M, Shimonogata T, Kumagai K, Ogita H, et al. Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure: A prospective study. J Am Coll Cardiol2000;35:40–413.

    Google Scholar 

  24. Solti F, Vecsey T, Kekesi V, Juhasz-Nagy A. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res1989;23:88–886.

    Google Scholar 

  25. Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation1997;96:168–1695.

    Google Scholar 

  26. Deedwania PC, Singh BN, Ellenbogen KA, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation1998;98:257–2579.

    Google Scholar 

  27. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, et al. Dofetililde in patients with congestive heart failure and left ventricular dysfunction. New Eng J Med1999;341:85–865.

    Google Scholar 

  28. Torp-Pedersen C, Moller M, Kober L, Camm AJ. Dofetilide for the treatment of atrial fibrillation in patients with congestive heart failure. Eur Heart J2000;21:120–1206.

    Google Scholar 

  29. Skanes AC, Krahn AD, Yee R, Klein GJ, Connolly SJ. Progression to chronic atrial fibrillation after pacing. The Canadian Trial of Physiologic Pacing. J Am Coll Cardiol2001;38:16–172.

    Google Scholar 

  30. Andersen HR, Thuesen L, Baggar JP, Vesterlund T, Thomsen PEB. Prospective randomised trial of atrial versus ventricular pacing in sick sinus syndrome. Lancet1994;344:152–1528.

    Google Scholar 

  31. Andersen HR, Nielsen JC, Thomsen PEB, et al. Longterm follow-up of patents from a randomized trial of atrial versus ventricular paicng in sick-sinus syndrome. Lancet1997;350:121–1216.

    Google Scholar 

  32. Mattioli AV, Vivoli D, Mattioli G. Influence of pacing modalities on the incidence of atrial fibrillation in patients without prior atrial fibrillation: A prospective study. Eur Heart J1998;19:28–286.

    Google Scholar 

  33. Lombardi F, Ravaglia R, Zardoni K, et al. Signs of sympathetic activation characterise patients with an early recurrence of atrial fibrillation after electrical cardioversion (Abstract). Eur Heart J1998;19(suppl):660.

    Google Scholar 

  34. Kontopoulos AG, Athyros VG, Papageorgiou AA, Boudoulas H. Effect of quinapril or metoprolol on circadian sympathetic and parasympathetic modulation after myocardial infarction. Am J Cardiol1999;84(10):110–1109.

    Google Scholar 

  35. Campbell RWF. ACE inhibitors and arrhythmias. Heart1996;76(Suppl. III):7–82.

    Google Scholar 

  36. Budaj A, Cybulski J, Cedro K, Karzmarewicz S, Maciejewicz J, et al. Effects of captopril on ventricular arrhythmias in the early and late phase of suspected acute myocardial infarction: Randomized, placebo-controlled substudy of ISIS-4. Eur Heart J1996;17:1506–1510.

    Google Scholar 

  37. Webster MWI, Fitzpatrick A, Nicholls G, Ikram H, Wells JE. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol1985;56:56–569.

    Google Scholar 

  38. Cleland JGF, Witte K, Thackray S. Bradykinin and ventricular function. Eur Heart J2000;2(suppl. H):H2–29.

    Google Scholar 

  39. Van Den Berg MG, Crijns HJGM, Veldhuisen DJV, et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Cardiac Failure1995;1(5):35–363.

    Google Scholar 

  40. Pedersen O, Bagger H, Kober L, Torp-Pedersen C on behalf of the TRACE Study Group. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation1999;100:37–380.

    Google Scholar 

  41. Packer M, Bristow MR, Cohn JN, Colluci WS, Fowler MB, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Eng J Med1996;334(21):134–1355.

    Google Scholar 

  42. Anonymous. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation1994;90(4):176–1773.

  43. Chadda K, Goldstein S, Byrington R, Curb JD. Effect of propanolol after acute myocardial infarction in patients with congestive heart failure. Circulation1986;73:50–510.

    Google Scholar 

  44. Cleland JGF, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blocking agents in heart failure, should they be used and how? Eur Heart J1996;17:162–1639.

    Google Scholar 

  45. Yusuf S, Sleight P, Rossi P, et al. Reduction in infarct size, arrhythmias and chest pain by early intravenous beta blockade in suspected acute myocardial infarction. Circulation1983;67:13–142.

    Google Scholar 

  46. Kennedy HL. Beta-blocker prevention of proarrhythmia and pro-ischemia: Clues from CAST, CAMIAT, and EMIAT. Am J Cardiol1997;80:120–1211.

    Google Scholar 

  47. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction. The CAPRICORN randomised trial. Lancet2001;357(9266):138–1390.

    Google Scholar 

  48. McMurray JJV, Dargie HJ, Ford I, et al. Carvedilol reduces supraventricular and ventricular arrhythmias after myocardial infarction: Evidence from the CAPRICORN study (Abstract). Circulation2001;104(17):3303.

    Google Scholar 

  49. Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. J Am Coll Cardiol2000;36:13–146.

    Google Scholar 

  50. Plewan A, Lehmann G, Ndrepepa G, Schreieck J, Alt EU, et al. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation. Sotalol vs Bisoprolol. Eur Heart J2001;2(16):150–1510.

    Google Scholar 

  51. Coumel P. Sotalol: A fool's deal? Eur Heart J2001;22(16):137–1373.

    Google Scholar 

  52. Camm AJ, Obel OA. Epidemiology and mechanism of atrial fibrillation and atrial flutter. Am J Cardiology1996;78(8A):–11.

    Google Scholar 

  53. Waktare JEP, Camm AJ. Atrial fibrillation begets trouble. Heart1997;77:39–394.

    Google Scholar 

  54. Van Gelder IC, Crijns HJGM, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol1991;68:4–46.

    Google Scholar 

  55. Van Gelder IC, Crijns HJGM, Lie KI. Characteristics of patients with atrial fibrillation and predictions of uneventful cardioversion. In: Atrial Fibrillation: A Treatable Disease? Dordrecht: Kluwer Academic Publishers, 1992:6–86.

    Google Scholar 

  56. Cappuci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J2000;21:6–73.

    Google Scholar 

  57. Lown B. Electrical cardioversion of cardiac arrythmia. British Heart Journal1967;29:46–487.

    Google Scholar 

  58. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol1997;27:38–390.

    Google Scholar 

  59. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation1996;94:161–1621.

    Google Scholar 

  60. Gosselink ATM, Crijns HJGM, Van Gelder IC, Hillege HL, Weisfield ACO, Lie KI. Low dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA1992;267:328–3293.

    Google Scholar 

  61. Middlekauf HR, Stevenson WG, Saxon LA, Stevenson LW. Low dose amiodarone for atrial fibrillation in advanced heart failure restores sinus rhythm and improves functional capacity (Abstract). Circulation1992;86:I–808.

    Google Scholar 

  62. Middlekauf HR, Stevenson WG, Stevenson LW, et al. Antiarrhythmic drug therapy in 367 heart failure patients: Class 1 drugs but not amiodarone are associated with increased sudden death risk (Abstract). J Am Coll Cardiol1991;17:(2)92A.

    Google Scholar 

  63. Weinberg BA, Miles WM, Klein LS, Bolander JE, Dusman RE, et al. Five-year follow-up of 589 patients with treated with amiodarone. Am Heart J1993;125:10–121.

    Google Scholar 

  64. Pedersen O, Bagger H, Keller N, Marchant B, Kober L, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function. Circulation2001;104:29–296.

    Google Scholar 

  65. Hoh ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. European Heart Journal1995;16:52–528.

    Google Scholar 

  66. Falk RH, Knowlton AA, Bernard SA, Gotlieb NE, Batinelli NJ. Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomised, double-blind trial. Ann Intern Med1987;106:50–596.

    Google Scholar 

  67. Hornestam B, carlsson T, Falk L, et al. Effects of intravenously administered digoxin in acute atrial fibrillation, compared to placebo (Abstract). Circulation1995;92:(8)–774

    Google Scholar 

  68. The digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Results of a randomized, placebo-controlled multicentre trial in 239 patients. European Heart Journal1997;18:64–654.

    Google Scholar 

  69. Jordaens L, Trouerbach J, Calle P, Tavernier R, Derycke E, et al. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J1997;18:64–648.

    Google Scholar 

  70. Singh BN, Mody FV, Lopez B, Sarma JSM. Antiarrhythmic agents for atrial fibrillation: Focus on prolonging atrial repolarization. Am J Cardiol1999;84(9A):16–173.

    Google Scholar 

  71. Paroxysmal atrial fibrillation. In: Coumel P, Leclerq JF, Attuel P, Kulbertus HE, Olsson SB, Schlepper M, eds. Atrial Fibrillation. Molndal: AB Hassle, 1982:15–175.

    Google Scholar 

  72. Newton GE, Tong JH, Schofield AM, Baines AD, Floras JS, Parker JD. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol1996;28:15–161.

    Google Scholar 

  73. Rawles JM, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: The effect of digoxin. Br Heart J1990;63:22–227.

    Google Scholar 

  74. Galun E, Flugelman MY, Glickson M, Eliakam M. Failure of long-term digitalisation to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest1991;99:103–1040.

    Google Scholar 

  75. Murgatroyd FD, Gibson SM, Baiyan X, O'Nunain S, Poloniecki Jd, et al. Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation1999;99(21):276–2770.

    Google Scholar 

  76. Van Gelder IC, Crijns HJGM, Van Gilst WH, Van Vijk LM, Hamer HPM, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or flutter. Am J Cardiol1989;64:131–1321.

    Google Scholar 

  77. Sodermark T, Jonsson B, Olsson A, Oro L, Wallin H. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm. Br Heart J1975;37:48–492.

    Google Scholar 

  78. Karlson BW, Torstensson I, Abjorn C, Jannson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation. A placebo-controlled one-year follow up study. European Heart Journal1988;9:28–290.

    Google Scholar 

  79. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obis-Manno D, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrythmia Suppression Trial. N Eng J Med1991;342(12):78–788.

    Google Scholar 

  80. Phillips E, Levine SA. Auricular fibrillation without other evidence of heart disease: A cause of reversible heart failure. Am J Med1949;7:478.

    Google Scholar 

  81. Amiodarone and amiodarone derivatives. In: Singh BH, Sarma JSM, Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL, eds. Cardiovascular Pharmacology and Therapeutics. New York: Churchill Livingstone, 1994:68–709.

    Google Scholar 

  82. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Metaanalysis of individual data from 6500 patients in randomised trials. Lancet1997;350:141–1424.

    Google Scholar 

  83. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, Simon P, EMIAT Investigators. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet1997;349:66–674.

    Google Scholar 

  84. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, et al. for The Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Eng J Med2000;342:91–920.

    Google Scholar 

  85. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol1997;30:79–798.

    Google Scholar 

  86. Gwilt M, Arrowsmith JE, Blackburn KJ, et al. UK-68,798: A novel potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther1991;256:31–324.

    Google Scholar 

  87. Carmeliet E. Voltage-and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther1992;262:80–817.

    Google Scholar 

  88. Green MS, Dorian P, Roy D, et al. A randomised, placebocontrolled comparison of intravenous dofetilide and procainamide in the acute conversion of atrial fibrillation/ flutter (Abstract). Circulation1997;96(Suppl. I):453–I-445.

    Google Scholar 

  89. Camm AJ. Reduction in hospitalisation for CHF in DIAMOND is due to the effect of dofetilide in patients with atrial fibrillation (Abstract). J Am Coll Cardiol2000;35:(2):153.

    Google Scholar 

  90. Kober L, Thomsen PEB, Moller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomised trial. Lancet2000;356:205–2058.

    Google Scholar 

  91. Tuinenberg AE, Van Gelder IC. Heart failure during atrial fibrillation is related to the presence and severity of the underlying disease (Abstract). Circulation1997;96(8):I–76.

    Google Scholar 

  92. Zehender M, Faber T, Jeron A, et al. Is conversion of atrial fibrillation the ultimate longterm goal? (Abstract). Circulation1995;92(8):I–775.

    Google Scholar 

  93. Kerr AJ, Simmonds MB, Stewart RAH. Influence of heart rate on stroke volume variability in atrial fibrillation in patients with normal and impaired left ventricular function. Am J Cardiology1999;82:149–1500.

    Google Scholar 

  94. Cleland JGF, Freemantle N, Mcgowan J, Clark A. The evidence for beta-blockers equals or surpasses that for ACE inhibitors in heart failure. BMJ1999;318:82–825.

    Google Scholar 

  95. Falk R, Leavitt JI. Digoxin for atrial fibrillation: A drug whose time has gone? Ann Intern Med1991;114:57–575.

    Google Scholar 

  96. Goldman S, Probst P, Selzer A, Cohn K. Inefficacy of “therapeutic” serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol1975;35:65–655.

    Google Scholar 

  97. Beasley R, Smith DA, Mchaffe DJ. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. BMJ1985;290(42):57–576.

    Google Scholar 

  98. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol1998;81:59–598.

    Google Scholar 

  99. Maragno I, Santostasi G, Gaion RM, Trento M, Grion AM. Low and medium dose diltiazem in chronic atrial fibrillation: Comparison with digoxin and correlation with drug plasma levels. Am H J1988;116:38–393.

    Google Scholar 

  100. Goldstein RE, Boccuzzi SJ, Cruess D. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation1991;83:5–60.

    Google Scholar 

  101. Figulla HR, Gletzen F, Zeymer U, Raiber M, Hegselmann J, et al. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy: Results of the diltiazem in dilated cardiomyopathy trial. Circulation1996;94(3):34–352.

    Google Scholar 

  102. Kudoh M. Clinical studies on long-term combined therapy of digitalis and xamoterol for patients with mild and moderate congestive heart failure accompanied by atrial fibrillation. Teikyo Medical Journal1988;16(1): 6–74.

    Google Scholar 

  103. Yahalom J, Klein HO, Kaplinsky E. Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation. Chest1977;71(5):59–596.

    Google Scholar 

  104. Cristodorescu R, Rosu D, Deutsch G, Verdes A, Luca C. The heart rate slowing effect of pindolol in patients with digitalis resistant atrial fibrillation and heart failure. Rev Roum Med-Med Int1986;24(3):20–215.

    Google Scholar 

  105. Khand AU, Rankin AC, Martin W, Taylor J, Gemmel I, Cleland JGF. Carvedilol or digoxin for the treatment of atrial fibrillation in heart failure patients? (Abstract). Eur Heart J2000;21(Suppl.):740.

    Google Scholar 

  106. Joglar JA, Acusta AP, Schusterman NH, Ramaswamy K, Kowal R, et al. Effect of carvedilol on survival and haemodynamics in patients with atrial fibrillation and left ventricular dysfunction: Retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J2001;142:49–501.

    Google Scholar 

  107. Atwood JE, Myers J, Sullivan MJ, Forbes SM, Sandhu S, Callaham P, Froelicher VF. The effect of cardioversion on maximal exercise capacity in patients with chronic atrial fibrillation. Am Heart J1989;118:91–918.

    Google Scholar 

  108. Ueshima K, Myers J, Morriss CK, Atwood JE, Kawaguchi T, Froelicher VF. The effect of cardioversion on exercise capacity in patients with atrial fibrillation. Am Heart J1993;126:102–1024.

    Google Scholar 

  109. Gosselink ATM, Crijns HJGM, Van Den Berg MP, Van Den Broek SA, Hillege HL, et al. Functional capacity before and after cardioversion of atrial fibrillation. Br Heart J1994;72:16–166.

    Google Scholar 

  110. Gosselink ATM, Bijlsma EB, Landsman ML, Crijns HJGM, Lie KI. Long-term effect of cardioversion on peak oxygen consumption in chronic atrial fibrillation. A 2 year follow-up. Eur Heart J1994;15:136–1372.

    Google Scholar 

  111. Kubac G, Malowany L. Functional capacity of patients with atrial fibrillation and controlled heart rate before and after cardioversion. Canadian Journal Cardiology1992;8:94–946.

    Google Scholar 

  112. Lundstrom T, Karlsson O. Improved ventilatory response to exercise after cardioversion of chronic atrial fibrillation to sinus rhythm. Chest1992;102:101–1022.

    Google Scholar 

  113. Hohnloser SH, Kuck KH, Lillenthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet2000;356:1789–1794.

    Google Scholar 

  114. AFFIRM Investigators. Atrial fibrillation follow-up investigations of rhythm management-The AFFIRM study design. The planning and steering committees of the AFFIRM study for the NHLBI AFFIRM Investigators. Am J Cardiol1997;79(9):119–1202.

    Google Scholar 

  115. Tunick PA, Mcelhaney L, Mitchell T, et al. The alternation between atrial flutter and atrial fibrillation. Chest1992;101:3–36.

    Google Scholar 

  116. Bianconi L, Boccadamo R, Pappalardo A, Gentili C, Pistolese M. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol1989;64:33–338.

    Google Scholar 

  117. Steinberg JS, Prasher S, Zelenkofske S, Ehlert FA. Radiofrequency catheter ablation of atrial flutter: Procedural success and long term outcome. Am Heart J1995;130:8–92.

    Google Scholar 

  118. Goldenberg IF, Lewis WR, Dias VC, Heywood JT, Pederson WR. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive cardiac failure. Am J Cardiol1994;74:88–889.

    Google Scholar 

  119. Dittrich HC, Erickson JS, Scheiderman T, Blacky R, Savides T, Nicod PH. Echocardiographic and clinical predictors for outcome of electrical cardioversion of atrial fibrillation. Am J Cardiol1989;63:106–1068.

    Google Scholar 

  120. Van Den Berg MP, Tuinenberg AE, Van Velduisen DJ, et al. Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure. Int J Cardiol1997;63:6–70.

    Google Scholar 

  121. Crijns HJGM, Van Gelder IC, Van Gilst WH, Hillege HL, Gosselink ATM, Lie KI. Serial antiarrythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or flutter. Am J Cardiol1991;68:33–341.

    Google Scholar 

  122. Coplen SE, Antmann EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A metaanalysis of randomised trials. Circulation1990;82:110–1116.

    Google Scholar 

  123. Twidale N, Sutton K, Dooley A, Winstanley S, Heedle W, et al. Effects on cardiac performance of atrioventricular node catheter ablation using radio-frequency current for drug-refractory atrial arrythmias. PACE1993;16(6):127–1284.

    Google Scholar 

  124. Brignole M, Gianfranchi L, Menozzi C, Bottoni N, Bollini R, et al. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol1994;74:24–246.

    Google Scholar 

  125. Edner M, Caidahl K, Bergfeldt L, Darpo B, Edvardsson N, Rosenqvist M. Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J1995;74:26–267.

    Google Scholar 

  126. Heinz G, Siostrzonek P, Kreiner G, Gossinger H. Improvement in left ventricular systolic function after successful radiofrequency his bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol1992;69:48–492.

    Google Scholar 

  127. Tieleman RG, Gosselinek ATM, Crijns HJGM, van Gelder IC, van den Berg MG. Efficacy, safety and determinants of conversion of atrial fibrillation or flutter with oral amiodarone. Am J Cardiol1997;79(1):5–57.

    Google Scholar 

  128. Porterfield JG and Porterfield IM. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol1989;63:11–116.

    Google Scholar 

Download references

Authors
  1. A.U. Khand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J.G.F. Cleland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P.C. Deedwania
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khand, A., Cleland, J. & Deedwania, P. Prevention of and Medical Therapy for Atrial Arrhythmias in Heart Failure. Heart Fail Rev 7, 267–283 (2002). https://doi.org/10.1023/A:1020097728178

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020097728178

Search

Navigation